1. Home
  2. STTK vs SHMD Comparison

STTK vs SHMD Comparison

Compare STTK & SHMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.35

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Logo SCHMID Group N.V. Class A Ordinary Shares

SHMD

SCHMID Group N.V. Class A Ordinary Shares

HOLD

Current Price

$5.92

Market Cap

216.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
SHMD
Founded
2016
1864
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.0M
216.2M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
STTK
SHMD
Price
$3.35
$5.92
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
429.0K
208.8K
Earning Date
11-06-2025
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,000,000.00
$85,165,542.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$1.86
52 Week High
$3.38
$6.70

Technical Indicators

Market Signals
Indicator
STTK
SHMD
Relative Strength Index (RSI) 72.56 63.97
Support Level $2.82 $4.70
Resistance Level $3.29 $5.40
Average True Range (ATR) 0.23 0.64
MACD 0.00 0.07
Stochastic Oscillator 93.75 77.36

Price Performance

Historical Comparison
STTK
SHMD

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About SHMD SCHMID Group N.V. Class A Ordinary Shares

Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

Share on Social Networks: